These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Irreversible opiate agonists and antagonists. II. Evidence against a bivalent mechanism of action for opiate azines and diacylhydrazones. Hahn EF; Nishimura S; Goodman RR; Pasternak GW J Pharmacol Exp Ther; 1985 Dec; 235(3):839-45. PubMed ID: 2416909 [TBL] [Abstract][Full Text] [Related]
4. Binding of a new opiate antagonist, nalmefene, to rat brain membranes. Michel ME; Bolger G; Weissman BA Methods Find Exp Clin Pharmacol; 1985 Apr; 7(4):175-7. PubMed ID: 2991678 [TBL] [Abstract][Full Text] [Related]
5. Effect of beta-FNA on opiate delta receptor binding. Rothman RB; Schumacher UK; Pert CB J Neurochem; 1984 Oct; 43(4):1197-200. PubMed ID: 6088697 [TBL] [Abstract][Full Text] [Related]
10. Application of an irreversible opiate antagonist (beta-FNA, beta-funal-trexamine) to demonstrate dynorphin selectivity for K-opioid sites. Huidobro-Toro JP; Yoshimura K; Way EL Life Sci; 1982 Nov; 31(22):2409-16. PubMed ID: 6130451 [TBL] [Abstract][Full Text] [Related]
11. Supersensitivity of brain opiate receptor subtypes after chronic naltrexone treatment. Tempel A; Zukin RS; Gardner EL Life Sci; 1982 Sep 20-27; 31(12-13):1401-4. PubMed ID: 6292636 [No Abstract] [Full Text] [Related]
12. Chronic naltrexone increases opiate binding in brain and produces supersensitivity to morphine in the locus coeruleus of the rat. Bardo MT; Bhatnagar RK; Gebhart GF Brain Res; 1983 Dec; 289(1-2):223-34. PubMed ID: 6318895 [TBL] [Abstract][Full Text] [Related]
13. Effect of intracerebroventricular beta-funaltrexamine on mu opioid receptors in the rat brain: consideration of binding condition. Liu-Chen LY; Yang HH; Li S; Adams JU J Pharmacol Exp Ther; 1995 Jun; 273(3):1047-56. PubMed ID: 7791074 [TBL] [Abstract][Full Text] [Related]
14. Irreversible opiate agonists and antagonists: the 14-hydroxydihydromorphinone azines. Hahn EF; Carroll-Buatti M; Pasternak GW J Neurosci; 1982 May; 2(5):572-6. PubMed ID: 6176696 [TBL] [Abstract][Full Text] [Related]
15. The irreversible narcotic antagonistic and reversible agonistic properties of the fumaramate methyl ester derivative of naltrexone. Takemori AE; Larson DL; Portoghese PS Eur J Pharmacol; 1981 Apr; 70(4):445-51. PubMed ID: 6263637 [TBL] [Abstract][Full Text] [Related]
16. beta-FNA binds irreversibly to the opiate receptor complex: in vivo and in vitro evidence. Rothman RB; Long JB; Bykov V; Jacobson AE; Rice KC; Holaday JW J Pharmacol Exp Ther; 1988 Nov; 247(2):405-16. PubMed ID: 2846819 [TBL] [Abstract][Full Text] [Related]
18. Reversible and irreversible binding of beta-funaltrexamine to mu, delta and kappa opioid receptors in guinea pig brain membranes. Tam SW; Liu-Chen LY J Pharmacol Exp Ther; 1986 Nov; 239(2):351-7. PubMed ID: 3021954 [TBL] [Abstract][Full Text] [Related]
19. Diastereomeric 6-desoxy-6-spiro-alpha-methylene-gamma-butyrolactone derivatives of naltrexone and oxymorphone. Selective irreversible inhibition of naltrexone binding in an opioid receptor preparation by a conformationally restricted michael acceptor ligand. Koolpe GA; Nelson WL; Gioannini TL; Angel L; Simon EJ J Med Chem; 1984 Dec; 27(12):1718-23. PubMed ID: 6209395 [TBL] [Abstract][Full Text] [Related]
20. Effects of intracerebroventricular beta-funaltrexamine on mu and delta opioid receptors in the rat: dichotomy between binding and antinociception. Liu-Chen LY; Li SX; Wheeler-Aceto H; Cowan A Eur J Pharmacol; 1991 Oct; 203(2):195-202. PubMed ID: 1666046 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]